2023 - Intravacc

Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention

NewsBy dg_admin 15/09/2023

Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention Intravacc’s recent research, featured in the peer-reviewed journal ‘Current Opinion in Immunology’ Volume 84 (2023), explores the potential of OMV-based vaccines in mucosal immunization. OMVs, derived from Gram-negative bacteria, demonstrate promise as versatile vaccine candidates. Administered intranasally, they exhibit the capacity to carry diverse…

Technician/Senior Technician Upstream Processing (USP)

VacancyBy dg_admin 23/08/2023

32/40 hours a week
Vacancy number 122023

Microencapsulated IL-12 Drives Genital Tract Immune Responses to Intranasal Gonococcal Outer Membrane Vesicle Vaccine and Induces Resistance to Vaginal Infection with Diverse Strains of Neisseria gonorrhoeae

Platforms OMV, Vaccine development servicesBy dg_admin 03/08/2023

Construction of a Vero Cell Line Expressing Human ICAM1 for the Development of Rhinovirus Vaccines

Platforms Cell based, Vaccine development services, VirusesBy dg_admin 03/08/2023

World Vaccine Congress Europe – Barcelona, October 16-19, 2023

EventBy dg_admin 18/07/2023

We are looking forward to seeing you at “World Vaccine Congress | Europe” from 16 until 19 October in Barcelona. Our Business Development Team will be happy to see you at booth #63 and Dinja Oosterhoff, PhD, Intravacc’s Vice President R&D, will give a lecture on Thursday 19 October 10:15 about “Vaccine development using Outer Membrane Vesicle platform technology”

Bio International Europe – Munich, November 6-9th, 2023

EventBy dg_admin 18/07/2023

Looking forward to network with you at Bio-Europe in Munich. Visit our booth (# to follow)

Enabling Tech Transfer of B. pertussis OMV Technology to our Partner Chonquing Zhifei Biological Products

NewsBy dg_admin 03/07/2023

Enabling Tech Transfer of B. pertussis OMV Technology to our Partner Chonquing Zhifei Biological Products In June, we successfully facilitated a Tech Transfer of “B. pertussis Outer Membrane Vesicle technology” to our colleagues from Zhifei at our laboratories in Bilthoven. This tech transfer is a testament to the strong relationship we built over the years…

Intravacc publishes 2022 annual report

NewsBy dg_admin 29/06/2023

Intravacc publishes 2022 annual report Bilthoven, the Netherlands, 29 June 2023 – Intravacc B.V., a leading CDMO for infectious diseases and therapeutic vaccines, announced today the publication of its 2022 annual report and the appointment of Frieda Gerdes, PhD as Vice President Business Development and Marketing. On May 3rd the Dutch State announced the sale…

Looking back on a successful Bio International 2023 in Boston!

NewsBy dg_admin 21/06/2023

Intravacc recently participated in the renowned “Bio International Conference” held in Boston.

Meet the new Business Development Team

NewsBy dg_admin 15/05/2023

Meet Intravacc’s new Business Development Team. A team of experienced professionals, dedicated to the success of your project.